Chimera Biotec

News Chimera Biotec

• Drug Development Technology: Frost & Sullivan Award goes to Imperacer

  The 2008 European Immunoassay Frost & Sullivan Excellence in Technology Award has been awarded to Chimera Biotec. Chimera Biotec is recognized for its pioneering Imperacer® ultra-sensitive immunoassay system, which has a 1000-fold better sensitivity compared to ELISA (Enzyme-linked Immunosorbent Ass more

• Chimera Biotec invites scientists to the III. Immunolympics 2008

  For the third time Chimera Biotec supports the scientific community with a contest on ultra-sensitive immunoassays, the III. Immunolympics are open. The contest seeks to find potential solutions to today's scientific challenges using ultra-sensitive immunoassays. It's the third time that Germany-b more

• CNS-Diagnostics: Chimera Biotec Starts Study on Novel Biomarker Detection for Alzheimer's Disease

  Chimera Biotec joins the EU funded EDAR project to adapt the Imperacer(TM) platform technology for the detection of novel biomarkers for the diagnosis of Alzheimer's disease. The consortium wants to find out whether the new markers can be used to test efficacy of new drugs, thereby contributing to n more

White papers Chimera Biotec

• Cytokine Quantification in Drug Development
  

  Immuno-PCR (IPCR) and ElectroChemiLuminescence (ECL) are technologies for improved performance of immunoassays. The specific advantages of the different technologies, using enzymatic or electrical signal amplification, allow for tailored assay design and address several specific challenges, such as maximum sensitivity up to 1 fg/ml target cytokine, simultaneous detection of multiple antigens, and high robustness against biological matrices more

• Clinical Biomarkers: Novel Tools for Pharmacodynamic Applications
  

  Biomarkers are currently changing the way we diagnose and treat diseases. Today pharmacodynamic biomarkers are widely used in the industry elaborating optimal dosing of new drugs and predictive biomarkers have an enormous potential for companion diagnostics more

• High sensitive detection of follistatin by Imperacer®: an initial study on the way to analytical gene-doping tests
  

  For the understanding of interactions in the muscle-growth directing myostatin-pathway and therefore also for the establishment of high sensitive detection strategies for gene-doping, detailed studies of protein concentration levels in biological matrices and appropriate highly sensitive analytic techniques for quantitative monitoring of these biomarkers are required. In this work, the development of a high sensitive assay for follistatin based on the Imperacer® technology is described. The quantification limit in human serum was found at 60 pg/ml in only 6 µl sample volume. With this initial assay we demonstrate the first application in a set of analytical tests for a high sensitive myostatin pathway related profiling. more

Publications Chimera Biotec

• Pharmacokinetics of natural mistletoe lectins after subcutaneous injection

  Purpose Knowledge of natural mistletoe lectins (nML) pharmacokinetics can be regarded as essential for further rational studies with mistletoe preparations. Studies with intravenous application of a recombinant type II ribosome inactivating protein (rML) analogous to nML revealed a short half-life o more

Websites Chimera Biotec